Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane

Journal of Microencapsulation

Volumn 30, Issue 5, 2013, Pages 432-440

  Li, Zhen ^a,b   Liu, Kexin ^b   Sun, Pengyuan ^b   Mei, Lin ^c   Hao, Tangna ^b   Tian, Yan ^b   Tang, Zeyao ^b   Li, Lei ^b   Chen, Dawei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Biodegradable polymers; Cancer nanotechnology; Cell uptake; Controlled release; Cytotoxicity; Exemestane; Montmorillonite

Indexed keywords

ALPHA TOCOPHEROL; EXEMESTANE; MONTMORILLONITE; NANOPARTICLE; POLYGLACTIN; TOCOFERSOLAN;

ARTICLE; CANCER CELL; CELL STRAIN CACO 2; CELL STRAIN MCF 7; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EVAPORATION; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MORPHOLOGY; NANOENCAPSULATION; PARTICLE SIZE; SOLVENT EXTRACTION; SURFACE CHARGE; THERMOGRAVIMETRY;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BENTONITE; BREAST NEOPLASMS; CACO-2 CELLS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84879595703     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.746749     Document Type: Article

References (34)

1. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev, 2011;63:170-83.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 1995;12:413-20.
3. Athanasiou KA, Niederauer GG, Agrawal C. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials, 1996;17:93-102. (Pubitemid 26031365)
4. Bertelli G, Gangadhara S. Exemestane in postmenopausal women with early or advanced breast cancer: A review. Expert Opin Pharmacother, 2010;11:1933-42.
5. Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. P-glycoprotein and surfactants: Effect on intestinal talinolol absorption. Clin Pharmacol Therap, 2005;77:24-32. (Pubitemid 40075386)
6. Clas SD, Dalton CR, Hancock BC. Differential scanning calorimetry: Applications in drug development. Pharm Sci Technolo Today, 1999;2:311-20. (Pubitemid 29378535)
7. Dong Y, Feng SS. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials, 2005;26:6068-76. (Pubitemid 40805612)
8. Eley JG, Pujari VD, McLane J. Poly(lactide-co-glycolide) nanoparticles containing coumarin-6 for suppository delivery: In vitro release profile and in vivo tissue distribution. Drug Deliv, 2004;11:255-61. (Pubitemid 39096044)
9. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly(lactide)-vitamin E derivative/ montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials, 2009;30:3297-306.
10. Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv, 2011;8:1407-24.
11. Holgado MA, Alvarez-Fuentes J, Fernandez-Arevalo M, Arias JL. Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer. Curr Drug Targets, 2011;12:1096-111.
12. Jain R. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide)(PLGA) devices. Biomaterials, 2000;21:2475-90.
13. Jukanti R, Sheela S, Bandari S, Veerareddy PR. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J Pharm Sci, 2011;100:3208-22.
14. Leonard A, Droy-Lefaix MT, Allen A. Pepsin hydrolysis of the adherent mucus barrier and subsequent gastric mucosal damage in the rat: Effect of diosmectite and 16,16 dimethyl prostaglandin E2. Gastroenterol Clin Biol, 1994;18:609-16. (Pubitemid 24261421)
15. Miyoshi Y, Murase K, Saito M, Oh K. Prediction of hormone sensitivity for breast cancers. Breast Cancer, 2010;17:86-91.
16. Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci, 2008;97:71-87.
17. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release, 2003;86:33-48. (Pubitemid 35469120)
18. Nabholtz JM. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag, 2008;4:189-204.
19. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials, 2008;29:2663-72.
20. Prasad YVR, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N, Takada K. Enhanced intestinal absorption of vancomycin with labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats. Int J Pharm, 2003;250:181-90. (Pubitemid 35447948)
21. Rivolta I, Panariti A, Lettiero B, Sesana S, Gasco P, Gasco MR, Masserini M, Miserocchi G. Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J Physiol Pharmacol, 2011;62:45-53.
22. Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK, Mukherjee R. Oral bioavailability enhancement of exemestane from Self-Microemulsifying Drug Delivery System (SMEDDS). AAPS PharmSciTech, 2009;10:906-16.
23. Shcharbin D, Pedziwiatr E, Blasiak J, Bryszewska M. How to study dendriplexes II: Transfection and cytotoxicity. J Control Release, 2010;141:110-27.
24. Sun B, Ranganathan B, Feng SS. Multifunctional poly(D,L-lactide-co- glycolide)/ montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials, 2008;29:475-86. (Pubitemid 350110345)
25. Traina TA, Poggesi L, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat, 2008;111:377-88.
26. Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol, 2005;59:355-64. (Pubitemid 40388090)
27. Wang J, Liu W, Tu Q, Wang J, Song N, Zhang Y, Nie N, Wang J. Folatedecorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. Biomacromolecules, 2011;12:228-34.
28. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2000, featuring the use of surveillance data for cancer prevention and control. J Nat Cancer Inst, 2003;95:1276-99. (Pubitemid 37160862)
29. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials, 2006;27:2285-91. (Pubitemid 41774539)
30. Yavuz B, Bilensoy E, Sumnu M. Bioavailability file: Exemestane. FABAD J Pharm Sci, 2007;32:79-89.
31. Yavuz B, Bilensoy E, Vural I, Sumnu M. Alternative oral exemestane formulation: Improved dissolution and permeation. Int J Pharm, 2010;398:137-45.
32. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, et al. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 2002;19:921-5. (Pubitemid 34804232)
33. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol, 1998;8:164-75. (Pubitemid 28323475)
34. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials, 2012;33:4889-906.